ArticlePaediatric drugs2017
Effectiveness and Safety of Different Once-Daily Doses of Adrenocorticotropic Hormone for Infantile Spasms.
Article in Paediatric drugs, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 20 citations in OpenAlex.
- Factors influencing adverse reactions to adrenocorticotropic hormone treatment in infantile epileptic spasm syndrome: a single-center retrospective study.Frontiers in pharmacology · 2026Article
- Infantile Spasms (West Syndrome): Integrating Genetic, Neurotrophic, and Hormonal Mechanisms Toward Precision Therapy.Medicina (Kaunas, Lithuania) · 2025Review
- The acid-base balance homeostasis reflected by urine pH in children with infantile epileptic spasm syndrome may be associated with response to adrenocorticotropic hormone treatment: a retrospective cohort study.Translational pediatrics · 2025Article
- The Enigma of West Syndrome: A Case of Infantile Spasms Without Genetic Clues.Case reports in pediatrics · 2025Article
- Intravenous versus intramuscular route of administration of natural adrenocorticotropic hormone in infantile epileptic spasm syndrome.Translational pediatrics · 2024Article
- [Factors influencing the efficacy of initial adrenocorticotropic hormone therapy for infantile epileptic spasms syndrome].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2023Article
- Integration of multiscale entropy and BASED scale of electroencephalography after adrenocorticotropic hormone therapy predict relapse of infantile spasms.World journal of pediatrics : WJP · 2022Article
- Assessing Risk for Relapse among Children with Infantile Spasms Using the Based Score after ACTH Treatment: A Retrospective Study.Neurology and therapy · 2022Article
- Etiologic Classification of 541 Infantile Spasms Cases: A Cohort Study.Frontiers in pediatrics · 2022Article
- Non-Canonical Effects of ACTH: Insights Into Adrenal Insufficiency.Frontiers in endocrinology · 2021Review
- West syndrome: a comprehensive review.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2020Review
- Neutrophil to lymphocyte rate and serum prealbumin maybe predictors for abnormal high blood pressure caused by adrenocorticotropic hormone therapy in children with epileptic spasms: two cases report.Annals of translational medicine · 2020Article
- Infantile Spasms in Children With Down Syndrome: Identification and Treatment Response.Global pediatric health · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAdrenocorticotropic hormone (ACTH) has been commonly used as a first-line treatment for infantile spasms (IS), but its optimal dose and duration are still unclear. This study is the largest retrospective cohort to document the therapeutic efficacy and tolerability for three gradient doses of ACTH in IU/kg/day units in Chinese patients.
objectiveThe aim of our study was to elucidate the effectiveness and safety of three different low doses and duration of ACTH treatment for IS in China.
methodsWe conducted a retrospective, chart review of IS cases that were treated with biologic short-acting ACTH and followed up for at least 6 months at a single center in China between June 2010 and June 2016. In total, 200 children met the inclusion criteria. Cases were divided into three groups according to dosage (1, 1.1-1.9, and 2-4 IU/kg/day). Furthermore, we divided the 2-4 IU/kg/day group into 2-3 and 3.1-4 IU/kg/day subgroups. All groups were evaluated for response rates, relapse rates, and adverse effects.
resultsElectroclinical remission by day 14 occurred in 41.4% of infants given 2-4 IU/kg/day and 36.4% of infants given 1.1-1.9 IU/kg/day, compared with only 14.7% of patients given 1 IU/kg/day (p = 0.004 and 0.03, respectively). Prolonging ACTH treatment for up to 28 days improved response by 24% in all 200 infants. Overall, 73.9% of infants receiving 2-4 IU/kg/day responded, significantly higher than the 52.7% responding to 1.1-1.9 IU/kg/day and the 23.5% responding to 1 IU/kg/day (p < 0.01). There was no significant difference in the number of relapses or adverse effects in the three groups. Moreover, in the 2-4 IU/kg/day group, 74.7% of children receiving 2-3 IU/kg/day of ACTH responded, compared with 70% who responded to 3.1-4 IU/kg/day (p = 0.78).
conclusionsACTH at a dosage of 2-3 IU/kg/day is superior to 1.1-1.9 and 1 IU/kg/day dosages, is as good as a 3.1-4 IU/kg/day dosage in terms of response rate, and causes no more adverse effects or relapses than other dosages. In addition, prolonging the duration of ACTH treatment can improve response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.